Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Electrophysiological Effects of LU111995 on Canine Hearts: In Vivo and In Vitro Studies

Eugene A. Sosunov, Ravil Z. Gainullin, Peter Danilo Jr., Evgeny P. Anyukhovsky, Michael Kirchengast and Michael R. Rosen
Journal of Pharmacology and Experimental Therapeutics July 1999, 290 (1) 146-152;
Eugene A. Sosunov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravil Z. Gainullin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Danilo Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evgeny P. Anyukhovsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kirchengast
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Rosen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We studied the electrophysiological effects of LU111995 (1–15 mg/kg p.o.) in conscious dogs with chronic atrioventricular block and ventricular pacing at 50 to 130 beats/min. LU111995 had no effects on idioventricular rhythm, QRS duration, and ventricular conduction time. It significantly prolonged Q–T interval (by 5–8%) and effective refractory period (ERP) (by 5–12%) with the maximal effect at 4 h after a 10 mg/kg dose. At 10 and 15 mg/kg, it increased the ERP/Q–T ratio. In vitro, the effects of LU111995 (1 × 10−7 to 1 × 10−5m) on action potentials of Purkinje fibers (PFs) and M cells were studied at cycle lengths (CL) of 300 to 2000 ms. It had no effects on maximum diastolic potential and action potential amplitude in either tissue. High concentrations induced a moderate, rate-independent decrease ofV˙max in M cells. In PFs and M cells, it produced reverse use-dependent lengthening of action potential duration (APD). In PFs at long CL, the drug exhibited a biphasic concentration-dependent effect on APD: maximum prolongation (by 26% at a CL of 2000 ms) was attained at 1 × 10−6m, and a decrease of APD occurred at higher concentrations. In M cells, the maximum effect on APD occurred at 3 × 10−6m. Early afterdepolarizations were seen in 50% of M cell preparations but only at CL of 2000 ms. Triggered activity did not occur. In summary, LU111995 prolongs the Q–T interval to a limited degree and is not arrhythmogenic over the physiological range of CLs.

Footnotes

  • Send reprint requests to: Michael R. Rosen, M.D., Gustavus A. Pfeiffer Professor of Pharmacology, Professor of Pediatrics, College of Physicians and Surgeons of Columbia University, Department of Pharmacology, 630 West 168 St., PH7 West-321, New York, NY 10032. E-mail: emf3{at}Columbia.edu

  • ↵1 This study was supported in part by U.S. Public Health Service National Heart, Lung, and Blood Institute Grant HL53956 and by Knoll AG.

  • ↵2 Present address: Knoll AG, Ludwigshaten, Germany.

  • Abbreviations:
    MDP
    maximum diastolic potential
    APD
    action potential duration
    EAD
    early afterdepolarization
    Vmax
    maximum rate of rise of phase 0
    ERP
    effective refractory period
    PF
    Purkinje fiber
    CL
    cycle length
    • Received January 7, 1999.
    • Accepted March 8, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 1
1 Jul 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Electrophysiological Effects of LU111995 on Canine Hearts: In Vivo and In Vitro Studies
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Electrophysiological Effects of LU111995 on Canine Hearts: In Vivo and In Vitro Studies

Eugene A. Sosunov, Ravil Z. Gainullin, Peter Danilo, Evgeny P. Anyukhovsky, Michael Kirchengast and Michael R. Rosen
Journal of Pharmacology and Experimental Therapeutics July 1, 1999, 290 (1) 146-152;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Electrophysiological Effects of LU111995 on Canine Hearts: In Vivo and In Vitro Studies

Eugene A. Sosunov, Ravil Z. Gainullin, Peter Danilo, Evgeny P. Anyukhovsky, Michael Kirchengast and Michael R. Rosen
Journal of Pharmacology and Experimental Therapeutics July 1, 1999, 290 (1) 146-152;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and β-Cell KATP Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics